The docetaxel potential in prostate tumor therapy increases upon upregulation of circ-Foxo3 and is related to Foxo3 and EMT suppression, thereby reducing the malignancy of cancer cells [123]. This evidence concerns the gene FOXO3 and prostate neoplasm.